2000, Volume 43

Guido Bold,* Karl-Heinz Altmann, Jörg Frei, Marc Lang, Paul W. Manley, Peter Traxler, Bernhard Wietfeld, Josef Brüggen, Elisabeth Buchdunger, Robert Cozens, Stefano Ferrari, Pascal Furet, Francesco Hofmann, Georg Martiny-Baron, Jürgen Mestan, Johannes Rösel, Matthew Sills, David Stover, Figan Acemoglu, Eugen Boss, René Emmenegger, Laurent Lässer, Elvira Masso, Rosemari Roth, Christian Schlachter, Werner Vetterli, Dominique Wyss, and Jeanette M. Wood: New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis.

Page 2316. In Table 3, the unit for c_{max} is wrong. The concentration should be given as $[\mu M]$. The correct version of Table 3 is as follows:

Table 3. Enzyme Inhibition of the 1-Anilino-(4-pyridylmethyl)phthalazine Derivatives CGP 79787D, 55-66, and SU 5416^a

				enzymatic inhibition				cellular ^c	pharmacokin.	
cpd	R	R'	R"	Flt-1		[µM] PDGF	^b c-Kit	ED ₅₀ [nM] KDR	c _{max} ^d [µM]	t _{max} [min]
CGP 79787D 55°	H H	CI H	H H	0.077 0.06	0.037 0.95	0.6 2.8	0.7 >10	34 200	32	15
56	Me	Н	Н	0.04	0.08	1	2.5	8	13	30
57°	Н	¹Bu	Н	0.24	0.21	2	1	9	25.6	30
58	Н	Ph	Н	0.23	0.20	1.4	1.4	85		
59	OMe	Н	Н	0.33	0.24	8.0	3	37	21	30
60	ОН	H	Н	0.08	0.67	4	7.9	250	0.5 ^f	30
61	CI	Cl	Н	0.07	0.03	0.6	0.7	27	9.8	30
62	OMe	CI	Н	0.26	0.14	2	3.5	24	8.0	30
63	Ме	Н	Me	0.15	0.04	0.8	2.0	10	10.0	30
64	CF ₃	CI	Н	0.6	0.3	4	2.7	27	7.6	120
65	CF₃	Н	Br	0.6	0.38	>10	>10	39	6.0	120
66	CF ₃	Н	F	0.35	0.20	>10	>10	40		
SU 5416				0.008	0.20	0.68	0.4	930	0.3	30

^a The data represent averages of at least three determinations. ^b PDGF- β receptor. ^c Inhibition of VEGF-driven cellular receptor autophosphorylation in CHO cells transfected with the KDR receptor. ^d The pharmacokinetic studies were performed in mice: Drug concentrations in blood samples were analyzed by reversed-phase HPLC 30, 60, 90, and 120 min after oral application of 50 mg/kg in a standardized formulation (DMSO/Tween 80). The value c_{max} represents the highest observed drug concentration at the indicated time point (t_{max}). ^e Dihydrochloride salt. ^f Low concentration of the parent compound but an apparently high concentration (not determined) of an unknown metabolite.

JM001010D

10.1021/jm001010d Published on Web 07/27/2000